8-K: Arbutus Reacquires Global Rights to Key Hepatitis B Drug Imdusiran, Forms Elite Scientific Advisory Board

Arbutus Biopharma Corporation has reacquired full global rights to its lead chronic hepatitis B compound, imdusiran, from Qilu Pharmaceutical without payment, and announced the formation of a new Scientific Advisory Board comprised of leading experts in the field.

Summary

• Arbutus Biopharma Corporation (Arbutus) and Qilu Pharmaceutical Co., Ltd. (Qilu) mutually agreed to terminate their strategic partnership for imdusiran in Greater China and Taiwan.
• All exclusive rights granted to Qilu for imdusiran in mainland China, Hong Kong, Macau, and Taiwan have reverted to Arbutus.
• No payments were associated with the termination of the License Agreement.
• The termination was driven by Qilu's pipeline reprioritization efforts and Arbutus's renewed focus on advancing its pipeline efficiently.
• Arbutus announced the formation of a new Scientific Advisory Board (SAB) composed of globally recognized leaders in chronic hepatitis B virus (cHBV) treatment with extensive experience in late-stage clinical trials.
• Imdusiran, an RNAi therapeutic, has achieved functional cure in eight patients in combination therapy across two Phase 2a clinical trials (IM-PROVE I and IM-PROVE II).

Sentiment

Score: 8

Explanation: The reacquisition of global rights to a promising lead compound without financial penalty, coupled with the formation of a high-caliber Scientific Advisory Board, represents a significant positive strategic advancement for Arbutus, enhancing its control over a key asset and its development trajectory.

Positives

• Arbutus has reacquired full global rights to its lead compound, imdusiran, in the significant Greater China and Taiwan markets, providing complete control over its development, manufacturing, and commercialization.
• The termination of the License Agreement incurred no associated payments, avoiding any financial penalty for Arbutus.
• Imdusiran has demonstrated promising clinical results, achieving functional cure in eight patients in Phase 2a trials, including two patients without interferon and seven with baseline HBsAg levels less than 1000 IU/mL.
• The establishment of a new Scientific Advisory Board with five globally recognized experts in cHBV treatment and late-stage clinical trials is expected to provide valuable strategic guidance for Arbutus's pipeline.

Negatives

• The termination of the strategic partnership with Qilu, while framed positively by Arbutus, indicates that Qilu no longer prioritized imdusiran in its pipeline, which could be interpreted as a subtle negative signal regarding the compound's perceived potential by a former partner.

Risks

• Ongoing and anticipated clinical trials for product candidates may be more costly or take longer to complete than anticipated, or may never be initiated or completed, or may not generate results that warrant future development.
• Arbutus may elect to change its strategy regarding its product candidates and clinical development activities.
• Arbutus may not receive the necessary regulatory approvals for the clinical development of its products.
• Economic and market conditions may worsen, impacting the company's operations and financial performance.
• Market shifts may require a change in strategic focus for Arbutus.
• There are ongoing lawsuits against Moderna and Pfizer/BioNTech regarding the use of Arbutus's patented LNP technology in their COVID-19 vaccines.

Future Outlook

Arbutus is renewing its focus on efficiently advancing its pipeline, particularly imdusiran, with the goal of achieving a functional cure for chronic HBV. The newly formed Scientific Advisory Board will provide strategic guidance for the company's cHBV programs, indicating a commitment to late-stage clinical development.

Management Comments

• Lindsay Androski, President and CEO of Arbutus: "I would like to express our deepest thanks to the executive leadership and team at Qilu for the collaborative and fruitful partnership we have enjoyed over the last several years. In light of Qilus pipeline reprioritization efforts and Arbutus renewed focus on advancing our pipeline efficiently, the parties have agreed to terminate our strategic partnership for Greater China. We are thrilled to once again hold global rights for imdusiran, which to date has achieved functional cure in eight patients in combination therapy in two Phase 2a trials."
• Dr. Weikang Tao, Global R&D Head of Qilu Pharmaceutical: "We greatly appreciate the collaboration, efforts and support of both Arbutus and Qilu's project teams for the development of imdusiran in the Greater China area and we wish Arbutus every success in further advancing the development of imdusiran."

Industry Context

The reacquisition of imdusiran rights positions Arbutus to directly address the significant unmet medical need of chronic HBV infection, which affects over 250 million people globally. This move aligns with the broader biopharmaceutical industry trend towards developing curative therapies for chronic viral diseases. The formation of a Scientific Advisory Board with prominent experts in hepatology and infectious diseases underscores Arbutus's commitment to rigorous clinical development and strategic pipeline management, a common practice among companies aiming for late-stage success in complex therapeutic areas.

Comparison to Industry Standards

• The newly formed Scientific Advisory Board includes globally recognized leaders in chronic HBV treatment, such as Dr. Edward J. Gane, who was involved in the early phase development of the first oral cure for hepatitis C and is now focused on developing a finite cure for hepatitis B.
• Dr. Anna Suk-Fong Lok, a member of the SAB, has published over 600 scientific articles, including guidelines on hepatitis B, demonstrating a high standard of expertise guiding Arbutus's strategy.
• Professor Man-Fung Yuen, another SAB member, has led most of the international trials examining novel agents for the treatment of chronic hepatitis B, indicating Arbutus is aligning with top-tier clinical trial leadership.
• The company's focus on achieving a 'functional cure' for HBV with imdusiran aligns with the highest aspirations in the field, moving beyond mere viral suppression.

Legal Proceedings

• Arbutus is consulting closely with and supporting its exclusive licensee, Genevant Sciences, to protect and defend its intellectual property, which is the subject of on-going lawsuits against Moderna and Pfizer/BioNTech for use of Arbutus's patented LNP technology in their COVID-19 vaccines.

Stakeholder Impact

• Shareholders: Potential positive impact due to the reacquisition of full global rights to a key asset (imdusiran) without cost, and enhanced strategic guidance from the new Scientific Advisory Board, which could increase the long-term value of the company's pipeline.
• Patients/Customers: Potential for accelerated and more direct development and commercialization of imdusiran in Greater China and Taiwan, potentially leading to broader access to a promising cHBV therapy.
• Employees: Continued focus on the development of a lead compound and pipeline, potentially ensuring job stability and future growth opportunities.
• Qilu Pharmaceutical: The termination allows Qilu to reprioritize its pipeline and allocate resources to other strategic areas.

Next Steps

• Arbutus will continue to advance its pipeline efficiently, with a renewed focus on imdusiran.
• The new Scientific Advisory Board will advise Arbutus on its strategic evaluation of its cHBV pipeline.
• Qilu Pharmaceutical will destroy or delete Arbutus Know-How and unused tangible materials within 30 days from June 20, 2025.
• Qilu Pharmaceutical will transfer all Regulatory Documents and Product Data related to imdusiran to Arbutus by June 30, 2025.

Key Dates

Recommendation

Keywords

Arbutus Biopharma, Imdusiran, AB-729, Hepatitis B, HBV, RNAi therapeutic, Qilu Pharmaceutical, License Agreement Termination, Greater China Rights, Scientific Advisory Board, Clinical Trials, Biopharmaceutical, Infectious Disease